Skip to content
AIPressRoom

FundingHealthcare & Biotech

Remedy Robotics Raises $62M to Advance Surgical Robotics

Remedy Robotics raised $62M Series B led by DCVC to develop AI-powered robotic systems for cardiovascular and neurovascular procedures.

Remedy Robotics raises $62M

The big picture: Remedy Robotics, a San Francisco-based medical technology company, has raised $62 million in Series B financing led by DCVC. The funding will support the development of its N1 robotic intervention system, designed for cardiovascular and neurovascular procedures.

Why it matters:

  • Expanding Access: Endovascular intervention is a critical treatment for stroke and cardiovascular emergencies, but access is severely limited, with only 2.8% of eligible stroke patients worldwide receiving mechanical thrombectomy.
  • Addressing Shortages: The company’s technology aims to address the global shortage of specialists capable of performing complex neurovascular and cardiovascular procedures, potentially expanding treatment availability beyond major medical centers.
  • Remote Capabilities: Remedy’s N1 system is being developed for on-site, remote, and potentially autonomous operation, which could enable specialists to perform procedures from a distance or with greater automation.

How it works:

  • Integrated Platform: The N1 platform combines robotics, machine learning, and advanced imaging technology to support endovascular procedures, which involve using catheters and other instruments to treat blood vessel conditions.
  • Advanced Features: The system is designed to analyze preoperative imaging, simulate procedures, and integrate real-time imaging during interventions, enhancing precision and efficiency.
  • Clinical Validation: The financing will support preparations for pivotal clinical trials and efforts to secure U.S. Food and Drug Administration approval for neurovascular procedures, building on successful remote neurointerventional procedures conducted in 2025.

The catch: Remedy’s N1 system remains under development and is not yet approved for sale or clinical use in any jurisdiction. Its proposed autonomous capabilities and broader clinical applications require further development, testing, and rigorous regulatory review in a competitive and highly scrutinized medical robotics market.

Key Facts

  • Company: Remedy Robotics
  • Amount: $62M
  • Round: Series B
  • Investors: DCVC (lead), UC Investments, Skip Capital, Hostplus, Build Collective, Blackbird, Divergent Capital, KdT Ventures
  • Founders: Dr. David Bell, Jake Sganga
  • Sector: Surgical AI Robotics
  • Headquarters: San Francisco, US

AIPressRoom Weekly

Every round we reported this week, the people behind the companies, and the events coming up. One email, every Tuesday.

More in Healthcare & Biotech

All